NCT05904938招募中不适用
Efficacy and Safety of Oral Administration of the Plant-based Complex Actitan-F in the Management of Chronic Paediatric Diarrhoea: a Double-blind, Placebo-controlled, Parallel-group Investigation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 136
- 试验地点
- 20
- 主要终点
- Change from baseline in stool consistency averaged over the 2-week Treatment Period
研究概览
简要总结
The goal of the study is to investigate the efficacy and safety of Lenodiar Pediatric (product under investigation) for the treatment of Chronic Diarrhoea (functional or post-infective diarrhoea) in children aged 1-5 years old, through a randomized, double blind, placebo-controlled clinical investigation
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
double blind
入排标准
- 年龄范围
- 1 Year 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children of either sex aged between 1-5 years (inclusive);
- •Diagnosis of chronic diarrhoea due to the following conditions:
- •Functional gastrointestinal disorder fulfilling Rome IV Criteria*
- •Functional gastrointestinal disorder fulfilling modified Rome IV Criteria **
- •Post-infectious diarrea with daily painless, recurrent passage of three or more large, unformed stools
- •Parents/legal guardians*** availability to fill on a daily basis the electronic daily diary by a smartphone/tablet.
- •Parents/legal guardians have given a written informed consent for participation in the investigation at the time of enrolment or before. The parent/legal guardian should also have agreed to bring the child for the visits scheduled in the protocol and to provide the requested information during the telephonic follow-up visit;
- •Parents/legal guardian able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgement;
- •Willingness not to make diet and lifestyle significant changes during the trial.
- •Rome IV criteria of functional diarrhoea (Neonate and Toddlers below 5 years), must include all of the following:
- •Daily painless, recurrent passage of four or more large, unformed stools
- •Symptoms last more than 4 weeks
- •Onset between 6 and 60 months of age
- •No failure-to-thrive if caloric intake is adequate
- •** Modified Rome IV criteria of functional diarrhoea (Neonate and Toddlers below 5 years), must include all of the following:
- •Daily painless, recurrent passage of three or more large, unformed stools
- •Symptoms last more than 2 weeks (Nelson Pediatric Texbook 21st Edition, Chronic diarrhea)
- •Onset between 6 and 60 months of age
- •No failure-to-thrive if caloric intake is adequate
- •These criteria have been modified in order to align the study to the functional diarrhoea condition in the real life.
- •Parent is the child's biological or adoptive parent. Legal guardian is defined as an individual who was authorized under applicable state or local law to consent on behalf of a child to general medical care, when general medical care includes participation in research. A guardian also meant an individual who was authorized to consent on behalf of a child to participate in research.
排除标准
- •Carbohydrate malabsorption, diagnosed either clinically (2 weeks exclusion diet with resolution of symptoms) or with proper testing (breath test)*;
- •Patients with any of the following chronic gastrointestinal disorders: inflammatory bowel disease, pancreatitis, chronic liver disease, eosinophilic oesophagitis, peptic ulcer disease, celiac disease, pseudo-obstruction, small bowel bacterial overgrowth, or Hirschsprung's disease
- •Significant chronic health condition requiring specialty care (e.g., lithiasis, ureteropelvic junction obstruction, sickle cell, cerebral palsy, hepatic, hematopoietic, renal, endocrine, or metabolic diseases) that could potentially impact the child's ability to participate or confound the results of the investigation;
- •Gastrointestinal blood loss;
- •Recurrent or unexplained fevers;
- •Developmental disabilities impairing ability to understand or communicate;
- •History of hypersensitivity or allergy to investigational product;
- •History of previous abdominal surgeries in the past 3 months;
- •Known hypersensitivity to any of the components (active ingredients or excipients) of the investigational product;
- •Conditions known to producing immunodeficiency (AIDS, other congenital immunodeficiency syndromes, drugs therapy with steroids, anticancer drugs, etc.);
- •Patients who have received any of the following treatments within the 2 weeks before the baseline visit:
- •Agents specially developed for achieving adsorbing properties, e.g. kaolin, pectin, bismuth subsalicylate;
- •Treatments that modify intestinal secretions, e.g. racecadotril;
- •Treatments that modify intestinal motility, e.g. opiates, anti-cholinergic agents;
- •Systemic Antibiotics;
- •Antiemetic agents.
- •Patients who have received probiotics and prebiotics within the 1 week before the baseline visit, unless they have been taken at stable dose (the use of probiotics and prebiotics in dairy food such as yoghurt, cheese, milk prior to the investigation is permitted);
- •Parents/legal guardians' refusal or inability to give written informed consent to participate in the investigation;
- •Parents/legal guardians who, in the opinion of the Investigator, are unable to fill up the electronic patient diary;
- •Patients who have participated in any other clinical trial in the last 3 months prior to the start of the investigation.
- •Applicable only for patients with Functional gastrointestinal disorder fulfilling Rome IV Criteria.
结局指标
主要结局
Change from baseline in stool consistency averaged over the 2-week Treatment Period
时间窗: Up to 2 weeks vs Baseline
Stool consistency will be assessed using the Bristol Stool Form Scale (BSFS) on a range from 1 (Hard Lumps) to 7 (Watery).
次要结局
- Change for daytime, nighttime, and 24-hour bowel movement frequency((Week1 to Week4) vs Baseline)
- Change for daytime, nighttime, and 24-hour urgency-free days((Week1 to Week4) vs Baseline)
- Change for daily daytime and nighttime stool consistency scores((Week1 to Week4) vs Baseline)
- Change for 24-hour abdominal pain scores((Week1 to Week4) vs Baseline)
- Time to event, with the event defined as the first week in which a reduction ≥50% of loose or watery stools as compared to baseline occurs.(through study completion, an average of 4 weeks)
- Use of other treatments (proportion of users) for diarrhea relief, evaluated by means of the electronic patient diaries;(through study completion, an average of 4 weeks)
- Change from baseline in stool consistency at day 3, day 7 and day 10.(Baseline to day 3, day 7 and day 10)
- Use of other treatments (quantity of other treatments) for diarrhea relief, evaluated by means of the electronic patient diaries;(through study completion, an average of 4 weeks)
- Change in results of the patient happiness using a weekly smiley likert scale(through study completion, an average of 4 weeks)
- Change in results in parent Quality of Life (100 mm VAS)(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Time to event, with the event defined as the first day in which loose or watery stools are not observed.(through study completion, an average of 4 weeks)
- Change in results of the Pediatric Quality of Life Questionnaires(Visit 1 (day 14); Visit 2 (day 28);)
- Change in patients' lifestyle(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Time to event, with the event defined as the third day of the first consecutive three days in which diagnostic criteria for chronic diarrhoea are no more met.(through study completion, an average of 4 weeks)
- Adverse Event(through study completion, an average of 4 weeks)
- Early withdrawal rate due to AEs(through study completion, an average of 4 weeks)
- Safety Endpoints - early withdrawal rate due to ADEs(through study completion, an average of 4 weeks)
- Serious Adverse Event(through study completion, an average of 4 weeks)
- Serious adverse device effects(through study completion, an average of 4 weeks)
- Adverse device effects(through study completion, an average of 4 weeks)
- Unexpected serious adverse device effects(through study completion, an average of 4 weeks)
- Weight(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Systolic/diastolic blood pressure(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Pulse(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Body Mass Index(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
- Waist circumference(Baseline to Visit 1 (day 14) and Visit 2 (day 28) and Visit 1 (day 14) to Visit 2 (day 28))
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
In Vivo Study of Sucrose and Liquid Oral Pediatric Medicines of Long-term Effect on Dental Biofilm pHDental Biofilm pHNCT01819350Federal University of Paraíba12
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
已完成
3 期
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)Crohn's DiseaseNCT00805766Tanabe Pharma Corporation39
已完成
1 期
Relative Bioavailability and Food Effect StudyPharmacology, ClinicalNCT01489488Bayer32
终止
1 期
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 DiabetesType 2 Diabetes MellitusNCT02020616Eli Lilly and Company60